Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04636307
Other study ID # ECR-RET-2020-15
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 22, 2021
Est. completion date March 22, 2025

Study information

Verified date February 2024
Source Association for Innovation and Biomedical Research on Light and Image
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non Proliferative Diabetic Retinopathy (NPDR).


Description:

The progression of diabetic retinopathy (DR) varies between different patients, even with similar metabolic control. It is becoming clear that a sizeable proportion of patients with mild non-proliferative diabetic retinopathy (NPDR) will take a long time to develop any sight-threatening complication. The inclusion of eyes/patients in a clinical trial that do not show any significant worsening during the period of the trial masks any beneficial effect of the drug being tested and consequently would increase trial sizes as the true therapeutic effect in high-risk patients would be partially obscured. It appears that the only option is to identify the eyes/patients that show progression of retinopathy during a pre-trial run-in period and only include such patients. Characterization of progressors in the early stages of DR and identification of biomarkers of disease progression are of major interest to facilitate drug development in this area of high unmet need. Three different phenotypes of mild NPDR progression with different risks for development of Clinically Significant Macular Edema (CSME) were identified using cluster analysis based on the turnover rate of microaneurysms (MAT) and the central retinal thickness (CRT). Phenotype A, patients with low MAT and CRT < 260 micron in women and < 275 micron in men (on Cirrus Optical Coherence Tomography - OCT, corresponding to the mean CRT in healthy subjects plus 1 standard deviation, SD); Phenotype B, patients with low MAT and CRT ≥ 260 micron in women and ≥ 275 micron in men; and Phenotype C patients with high MAT. These phenotypes were recently confirmed in a larger population of NPDR patients. In this study, Phenotype B shows a risk for DR progression to Macular Edema (ME) of OR=13.30 and Phenotype C of OR=6.32. When CRT increase is present, then Phenotype C shows a higher risk for ME (OR=29.02). In these studies, the occurrence of proliferative diabetic retinopathy (PDR) as an outcome was rare and did not allow statistical analysis. More recently it was shown that phenotype C identifies eyes at higher risk for development of CSME and PDR, whereas phenotype A identifies eyes at very low risk for vision-threatening complications. Patients with phenotypes B and C are, therefore, the NPDR patients with higher risk for ME development and are those patients who may benefit from early therapeutic or preventive treatment. Therefore, a proper characterization of this population is of major interest for the understanding of the disease, and to the design of new therapeutical approaches that can facilitate adequate and timely interventions. To better characterize these patients, new non-invasive methods are now available that allow for a better insight of the retinal changes that occurs in these patients. The Optical Coherence Tomography Angiography (OCT-A) and OCT-Leakage (OCT-L) are two of these methods that can be used in longitudinal studies. These methods allow to quantify capillary closure and leakage, the main alterations occurring in DR (ischemia and leakage) and which are considered to predict sight-threatening complications, ME and PDR. In recent studies it was shown that the vessel density in the superficial and deep layers, obtained with OCT-A, and the Low Optical Reflectivity (LOR) ratio obtained with OCT-L are altered even in the earlier stages of DR. These two methods are therefore expected to better characterize leaky and ischemic patients' phenotypes (i.e., phenotypes B and C, respectively), being therefore a major step in early diagnosis and timely treatment of DR patients. Measurement of neurodegeneration (ND) represented by thinning of Ganglion Cell Layer (GCL) and Inner Plexiform Layer (IPL) will also be performed. This study aims to better characterize the retinal changes that occur during a 2-years follow-up period in patients with diabetes Type 2 and with the initial stages of NPDR and at higher risk for sight-threatening complications, allowing better characterization of eyes at risk of progression (phenotypes B and C). The inclusion will be based on patients with established retinopathy ETDRS 35, 43, 47 and 53, distributed to the different clinical sites in the study, creating the opportunity to demonstrate the progression phenotypes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 202
Est. completion date March 22, 2025
Est. primary completion date March 21, 2023
Accepts healthy volunteers
Gender All
Age group 35 Years to 90 Years
Eligibility INCLUSION CRITERIA - Diabetes type 2 according to 1985 WHO criteria; - Age between 35 and 90 years; - NPDR levels 35, 43, 47 or 53 (based on the ETDRS criteria - 7 fields CFP) after confirmation by the Reading Centre; - Refraction with a spherical equivalent less than 5 Dp; - Informed consent. EXCLUSION CRITERIA - Repeated HbA1C > 10% in the first visit; - Cataract or other eye disease that may interfere with fundus examinations; - Age-related macular degeneration, glaucoma, vitreomacular disease, or other retinal vascular disease, or any ocular condition that, in the opinion of the investigator may affect retinopathy status or alter visual acuity during the study; - Any eye surgery within a period of 6-months; - Previous laser treatment or previous intravitreal injections; - Any patient comorbidity likely to affect the eye and not related with diabetes or cardiovascular disease; - Presence of CIME (CRT = 290 µm in women and = 305 µm in men) with vision loss or needing immediate treatment, according to clinical practice; - Dilatation of the pupil < 5 mm; - Uncontrolled systemic hypertension (values outside normal range: systolic 70-210 mmHg and diastolic 50-120 mmHg).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Biomarkers
To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.

Locations

Country Name City State
France CS042 - Department of Ophthalmology, University Hospital, CHU Dijon Dijon
Italy CS067- Department of Ophthalmology, University Vita Salute - Scientific Institute of San Raffael, Milan Milan
Italy CS063 - Excellence Eye Research Centre, University G. d'Annunzio of Chieti-Pescara Pescara
Italy CS020 - G. B. Bietti Eye Foundation - IRCCS Roma
Portugal CS001 Centre for Clinical Trials - AIBILI Coimbra

Sponsors (2)

Lead Sponsor Collaborator
Association for Innovation and Biomedical Research on Light and Image European Vision Institute Clinical Research Network

Countries where clinical trial is conducted

France,  Italy,  Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary DRSS severity progression DRSS severity progression of one, two or more ETDRS step changes 36 months
Primary Progression to vision-threatening complications CIME defined as eyes with a CRT = 290 µm in women and = 305 µm in men (Zeiss Cirrus SD-OCT); CSME identified on clinical evaluation as defined by ETDRS by retinal thickening within 500 µm of the center of the fovea or presence of hard exudates (with thickening of the adjacent retina) within 500 µm of the center of the fovea, or thickening of at least 1 disc area located less than 1 disc diameter from the center of the fovea. (Zeiss Cirrus SD-OCT); PDR identified by the presence of abnormal new vessels in the retina. 36 months
Primary Presence of ischemia dentified by decrease of 2 or more Standard deviations (in relation to healthy control population) on the values of vessel density, perfusion density or FAZ circularity. 36 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2